CAAS Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

CAAS Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-43,000	Closed	-$5.57M	–	894
2022 Q4	$5.57M	Hold	43,000	–	–	0.34%	93
2022 Q3	$4.75M	Hold	43,000	–	–	0.23%	136
2022 Q2	$3.22M	Hold	43,000	–	–	0.16%	157
2022 Q1	$3.36M	Sell	43,000 -29,000	-40%	-$2.22M	0.14%	172
2021 Q4	$6.48M	Hold	72,000	–	–	0.16%	152
2021 Q3	$6.66M	Hold	72,000	–	–	0.13%	162
2021 Q2	$5.6M	Buy	+72,000	New	+$5.46M	0.09%	220
2021 Q1	–	Sell	-121,300	Closed	-$20.7M	–	1380
2020 Q4	$20.7M	Buy	+121,300	New	+$18M	0.2%	109

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAAS Capital Management's SRPT Position: Q1 2023 in Review

CAAS Capital Management sold out of Sarepta Therapeutics (SRPT) in Q1 2023, closing a stake of 44,929 shares — an estimated $5.82M sold.

CAAS Capital Management first reported a position in SRPT in Q1 2021 and held it in 8 quarters. The position peaked at $7.96M in Q4 2021. 425 funds tracked by Wall St. Rank hold SRPT as of Q1 2023.

CAAS Capital Management reported no remaining Sarepta Therapeutics position as of Q1 2023 after selling out during the quarter.
CAAS Capital Management sold 44,929 Sarepta Therapeutics shares in Q1 2023, an estimated $5.82M.
CAAS Capital Management first reported a position in Sarepta Therapeutics in Q1 2021 and held it in 8 quarters.
CAAS Capital Management's Sarepta Therapeutics position peaked at $7.96M in Q4 2021.
425 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2023.

Based on CAAS Capital Management's 13F filing for Q1 2023, filed 15 May 2023.